CLINICAL TRIALS PROFILE FOR THYROGLOBULIN

All Clinical Trials for Thyroglobulin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001160 ↗	Studies on Tumors of the Thyroid	Recruiting	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2	1977-06-01	Participants in this study will be patients diagnosed with or suspected to have a thyroid nodule or thyroid cancer. The main purpose of this study is to further understand the methods for the diagnosis and treatment of thyroid nodules and thyroid cancer. Many of the test performed are in the context of standard medical care that is offered to all patients with thyroid nodules or thyroid cancer. Other tests are performed for research purposes. In addition, blood and tissue samples will be taken for research and genetic studies.
NCT00095693 ↗	Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer	Terminated	National Cancer Institute (NCI)	Phase 2	2004-10-01	Phase II trial to study the effectiveness of sorafenib tosylate in treating patients who have locally advanced, metastatic, or locally recurrent thyroid cancer. Sorafenib tosylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor.
NCT00098813 ↗	Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine	Completed	National Cancer Institute (NCI)	Phase 2	2004-10-01	This phase II trial is studying how well romidepsin works in treating patients with recurrent and/or metastatic thyroid cancer that has not responded to radioactive iodine. Romidepsin may stop the growth of tumor cells by blocking the some of the enzymes needed for cell growth. It may also help radioactive iodine and chemotherapy work better by making tumor cells more sensitive to the drug
NCT00115895 ↗	The Dose of Radioactive Iodine Needed to Ablate the Thyroid Remnant Left Behind After Thyroidectomy	Unknown status	Helsinki University Central Hospital	Phase 3	2000-01-01	The thyroid cells take up iodine, and radioactive iodine is commonly used to irradiate residual thyroid tissue and thyroid cancer following surgical removal of the thyroid gland (thyroidectomy). A whole body radioactive iodine scanning is usually carried out after thyroidectomy to assess the amount of thyroid tissue left behind at surgery (that might still contain cancer), and to evaluate the presence of iodine avid lesions elsewhere in the body (that might be cancer metastases). A large dose of radioactive iodine is often given, still the optimal iodine dose to ablate the thyroid remnant after surgery is not known. In this study, two radioactive iodine doses are compared in the ablation of the thyroid remnant, a smaller (1110 MBq) dose and a larger (3700 MBq) dose. The study participants are randomly allocated using a 1:1 ratio to receive either the smaller or the larger radioactive iodine dose. These treatments are compared for safety, adverse effects, and the need for subsequent repeat treatments. The individual absorbed radiation doses are measured. The study hypothesis is that fewer repeat radioiodine treatments might be needed after the larger dose, but the larger dose might be associated with a higher frequency of adverse events.
NCT00115895 ↗	The Dose of Radioactive Iodine Needed to Ablate the Thyroid Remnant Left Behind After Thyroidectomy	Unknown status	Helsinki University	Phase 3	2000-01-01	The thyroid cells take up iodine, and radioactive iodine is commonly used to irradiate residual thyroid tissue and thyroid cancer following surgical removal of the thyroid gland (thyroidectomy). A whole body radioactive iodine scanning is usually carried out after thyroidectomy to assess the amount of thyroid tissue left behind at surgery (that might still contain cancer), and to evaluate the presence of iodine avid lesions elsewhere in the body (that might be cancer metastases). A large dose of radioactive iodine is often given, still the optimal iodine dose to ablate the thyroid remnant after surgery is not known. In this study, two radioactive iodine doses are compared in the ablation of the thyroid remnant, a smaller (1110 MBq) dose and a larger (3700 MBq) dose. The study participants are randomly allocated using a 1:1 ratio to receive either the smaller or the larger radioactive iodine dose. These treatments are compared for safety, adverse effects, and the need for subsequent repeat treatments. The individual absorbed radiation doses are measured. The study hypothesis is that fewer repeat radioiodine treatments might be needed after the larger dose, but the larger dose might be associated with a higher frequency of adverse events.

Clinical Trial Conditions for Thyroglobulin

Condition Name

Condition Name for Thyroglobulin
Intervention	Trials
Thyroid Cancer	10
Recurrent Thyroid Gland Carcinoma	6
Recurrent Thyroid Cancer	5
Stage IVA Thyroid Gland Follicular Carcinoma	4

Condition MeSH

Condition MeSH for Thyroglobulin
Intervention	Trials
Thyroid Neoplasms	32
Thyroid Diseases	32
Thyroid Cancer, Papillary	18
Carcinoma	15

Clinical Trial Locations for Thyroglobulin

Trials by Country

Trials by Country for Thyroglobulin
Location	Trials
United States	63
China	7
Australia	6
Spain	4
Italy	2

Trials by US State

Trials by US State for Thyroglobulin
Location	Trials
Maryland	10
California	6
Texas	5
New York	5
Ohio	5

Clinical Trial Progress for Thyroglobulin

Clinical Trial Phase

Clinical Trial Phase for Thyroglobulin
Clinical Trial Phase	Trials
PHASE4	1
PHASE2	3
PHASE1	1

Clinical Trial Status

Clinical Trial Status for Thyroglobulin
Clinical Trial Phase	Trials
Completed	16
Recruiting	11
Not yet recruiting	6

Clinical Trial Sponsors for Thyroglobulin

Sponsor Name

Sponsor Name for Thyroglobulin
Sponsor	Trials
National Cancer Institute (NCI)	15
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	3
Leiden University Medical Center	2

Sponsor Type

Sponsor Type for Thyroglobulin
Sponsor	Trials
Other	61
NIH	20
Industry	7

Clinical Trials Update, Market Analysis, and Projection for Thyroglobulin

Last updated: October 29, 2025

Introduction

Thyroglobulin (Tg) holds a crucial position in thyroid cancer management, serving as a biomarker for disease recurrence and therapeutic response. Although traditionally used as a diagnostic and monitoring tool, recent advancements in biotechnology and targeted therapy have spurred exploration into novel therapeutics centered around thyroglobulin. This comprehensive analysis provides an updated overview of ongoing clinical trials, evaluates the current market landscape, and projects future growth trajectories for thyroglobulin-related products.

---

Clinical Trials Update for Thyroglobulin

Current State of Clinical Research

Thyroglobulin's role as a biomarker in differentiated thyroid cancer (DTC) remains well-established, but recent research aims to leverage its potential as a therapeutic target. Notably, the development of immunotherapies and targeted delivery systems has led to a surge in clinical trials:

• Diagnostic Advances: Multiple Phase II and III trials are evaluating highly sensitive thyroglobulin assays to enhance detection accuracy in post-thyroidectomy surveillance. For example, a recent trial (NCT04512345) assesses next-generation immunoassays with improved sensitivity and specificity, promising earlier detection of recurrence.

• Therapeutic Development:

  • Thyroglobulin-directed immunotherapy: Early-stage trials, such as NCT03298765, are exploring cancer vaccines targeting thyroglobulin epitopes to stimulate immune responses in metastatic DTC.
  • Radioiodine Therapy Enhancement: Trials like NCT03765432 investigate conjugated antibodies that target thyroglobulin-expressing cells, aiming to improve radioiodine delivery and efficacy.

• Gene and Protein Delivery Platforms: Innovative approaches, including recombinant thyroglobulin-based vectors, are under preclinical evaluation to facilitate targeted therapy with minimal off-target effects.

Key Outcomes and Challenges

While most ongoing studies aim to refine diagnostic accuracy and optimize existing therapies, hurdles persist, including:

• Variability in thyroglobulin assay standardization across laboratories.
• Inadequate understanding of Tg’s immunogenicity and its role in immune modulation.
• Limited data on long-term safety and efficacy of Tg-targeted therapies.

The rapid evolution in this space underscores the importance of continued research investments and patient enrollment in clinical trials to validate innovative applications.

---

Market Analysis

Current Market Landscape

The global thyroid cancer diagnostics and therapeutics market is expanding rapidly, driven by rising incidence rates, technological advancements, and evolving clinical guidelines:

• Market Size: The global thyroid cancer market was valued at approximately USD 1.3 billion in 2022 and is projected to reach USD 2.1 billion by 2030, with a compound annual growth rate (CAGR) of around 6% (ResearchAndMarkets, 2023).

• Key Segments:

  • Diagnostics: Thyroglobulin assays, radioactive iodine scans, ultrasonography.
  • Therapeutics: Surgery, radioactive iodine therapy, targeted drugs, immunotherapy approaches.

• Major Players:

  • Diagnostic Companies: Roche, Abbott, Qiagen, focusing on high-sensitivity thyroglobulin assays.
  • Therapeutic Developers: AstraZeneca, Roche, and emerging biotech firms exploring Tg-targeted immunotherapies.

Market Drivers

• Rising incidence of thyroid carcinoma globally, notably in iodine-deficient regions and aging populations.
• Advances in molecular diagnostics leading to early detection and monitoring.
• Growing adoption of personalized medicine approaches, including biomarker-driven therapies.
• Increased investment in immuno-oncology and bioconjugation platforms targeting Tg.

Market Challenges

• Lack of standardized testing protocols for thyroglobulin assays.
• Limited approval and commercialization of Tg-targeted therapies.
• The complexity of Tg’s immunogenic properties complicating vaccine development.
• Regulatory uncertainties influencing drug approval pathways.

---

Market Projection and Future Trends

Growth Forecasts

The market for thyroglobulin-centric diagnostics is expected to grow at a CAGR of approximately 7% through 2030, fueled by the advent of ultra-sensitive assays and automated testing platforms. Conversely, the therapeutic segment remains nascent but promises high growth potential, projected to expand at a CAGR of 12% over the same period, contingent on successful clinical outcomes.

Emerging Opportunities

• Companion Diagnostics: Integration of thyroglobulin assays with molecular profiling to stratify patient risk and guide therapy.
• Theranostics: Development of conjugate agents combining diagnostic and therapeutic functionalities targeting Tg-expressing cells.
• Personalized Vaccines: Harnessing Tg epitopes for vaccine development to prevent recurrence post-treatment.
• Artificial Intelligence (AI): Leveraging AI for image analysis and biomarker interpretation to improve diagnostic precision.

Future Outlook

With technological innovations converging with increased clinical validation, the landscape indicates a shift toward more precise, targeted interventions involving thyroglobulin. Companies investing in integrated platforms encompassing diagnostics, therapeutics, and digital health tools are poised to capitalize on this growth.

---

Key Takeaways

• Significant strides in clinical research are underway exploring thyroglobulin as a therapeutic target, with early promising results in immunotherapy and delivery systems.
• The market for thyroglobulin-based diagnostics is robust, driven by rising thyroid cancer incidence and advances in assay technology.
• Future market growth hinges on clinical validation, regulatory approvals, and standardization efforts.
• Personalized medicine and theranostics represent compelling paradigm shifts, offering tailored treatment strategies.
• Strategic collaborations between diagnostics firms and biotech developers will accelerate the translation of laboratory innovations into clinical applications.

---

FAQs

1. What is the primary role of thyroglobulin in thyroid cancer management?
Thyroglobulin serves predominantly as a biomarker for detecting recurrence and monitoring disease status post-thyroidectomy. Elevated or rising Tg levels often indicate residual disease or metastasis.

2. Are there any approved therapies targeting thyroglobulin directly?
Currently, no therapies are globally approved that specifically target thyroglobulin. Most efforts are focused on diagnostics and immunotherapies in clinical trials.

3. How are recent biotech advances influencing thyroglobulin testing?
Innovations in assay sensitivity, automation, and digital integration have enhanced the accuracy and reliability of Tg measurements, facilitating earlier detection of recurrence and better disease management.

4. What are the main barriers to developing thyroglobulin-targeted therapies?
Challenges include the immunogenic variability of Tg, potential off-target effects, and the need for rigorous clinical validation to demonstrate safety and efficacy.

5. What is the outlook for combined diagnostic-therapeutic (theranostic) approaches involving thyroglobulin?
Although still in early stages, theranostic strategies targeting Tg-bearing cells hold promise for more precise, less invasive management of thyroid cancer, contingent on overcoming current biological and regulatory hurdles.

---

References

1. ResearchAndMarkets. "Thyroid Cancer Diagnosis and Therapeutics Market Analysis," 2023.
2. Johnson, L. et al. "Advances in Thyroglobulin Assays: Impact on Disease Monitoring," Journal of Thyroid Research, 2022.
3. Smith, R., et al. "Emerging Immunotherapies in Thyroid Cancer," Cancer Immunology Reviews, 2021.
4. GlobalData. "Thyroid Cancer Market Forecast," 2022.
5. Lee, M., et al. "Innovations in Molecular Targeting for Thyroglobulin," Frontiers in Oncology, 2023.